Short answer
Atrium Therapeutics, Inc. (RNA) filed an 8-K current report with the SEC on August 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results.
Atrium Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Item 2.02 incorporates Exhibit 99.1, which contains Atrium Therapeutics’ fiscal-year 2026 results
- Results are furnished rather than filed, limiting Exchange Act Section 18 liability and automatic incorporation into other filings
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $20.2M, or $1.18 per share, versus $12.9M, or $0.75, year-over-year
- FDA IND clearance enables ATR 1072’s Corventis Phase 1/2 trial, targeting approximately 37 PRKAG2 syndrome participants
- Corventis first enrollment remains expected by year-end 2026, with initial proof-of-concept data targeted for second half 2027
- BMS collaboration generated a $15M milestone payment in August, to be recognized in Q3 2026
- Cash, equivalents and short-term investments totaled $263.9M, supporting planned operations through mid-2028 including the BMS payment
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Atrium Therapeutics, Inc. 8-K filings
Get the next RNA 8-K as it lands
Follow RNA for push alerts, or ask the research agent what this filing means.